Clinical trials: Plasma Renin Activity
Coronary Artery Disease (CAD), Coronary Atherosclerosis
Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients
The study will assess the change in coronary atherosclerotic disease as determined by intravascular ultrasound (IVUS) for aliskiren compared to placebo when given in addition to standard therapy in patients with coronary artery…
- Trial name
- AQUARIUS (NCT00853827)
- Testing
- Aliskiren
- Where
- 129 sites in United States, Argentina and 9 more
- Volunteers
- 613 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure
Effects of Aliskiren, Ramipril, and the Combination on Levels of Angiotensin II in Patients With Decompensated Systolic Heart Failure
In addition to the blood pressure lowering effects of aliskiren, it may have beneficial effects on blocking the so called RAAS (renin-angiotensin-aldosterone system) at the tissue level.
- Trial name
- ESCAPE-SHF (NCT00923156)
- Testing
- aliskiren, ramipril
- Where
- 16 sites in Germany, Poland and 1 more
- Volunteers
- 123 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
A Study to Evaluate the Safety/Tolerability and Pharmacokinetics of Aliskiren in Hypertensive Pediatric and Adolescent Patients 6-17 Years of Age
This first open-label study in a pediatric population was designed to evaluate aliskiren safety and pharmacokinetics after single and multiple dosing in 6-17 year old children with hypertension.
- Trial name
- NCT00834041
- Testing
- Aliskiren 3.125 mini-tablets
- Where
- 5 sites in United States, Belgium and 3 more
- Volunteers
- 39 people
- Sponsor
- Novartis
Acute Decompensated Heart Failure, Congestive Heart Failure
Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure
This study evaluated the effect of early initiation of aliskiren therapy, compared to standard therapy, in the reduction of cardiovascular death and heart failure re-hospitalization events within 6 months, in congestive heart…
- Trial name
- ASTRONAUT (NCT00894387)
- Testing
- Aliskiren
- Where
- 308 sites in United States, Argentina and 22 more
- Volunteers
- 1,639 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Heart Failure
Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure
The study will evaluate the efficacy and safety of both aliskiren monotherapy and aliskiren/enalapril combination therapy as compared to enalapril monotherapy, on morbidity and mortality in patients with chronic heart failure…
- Trial name
- ATMOSPHERE (NCT00853658)
- Testing
- Enalapril, Aliskiren
- Where
- 806 sites in United States, Argentina and 42 more
- Volunteers
- 7,064 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension, Plasma Renin Activity
A Pilot Study of Plasma Renin Activity Guided vs Generic Combination Therapy for Hypertension
The purpose of this study is to investigate the effect of plasma renin activity-guided therapy for determining hypertension treatment.
- Trial name
- NCT01658657
- Testing
- Hydrochlorothiazide, Lisinopril, Amlodipine
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of North Carolina, Chapel Hill